[{"data":1,"prerenderedAt":194},["ShallowReactive",2],{"drug-zolmitriptan":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":44,"contraindications":75,"warnings":92,"renal":100,"monitoring":101,"interactions":102,"review":103,"examples":106,"atc":112,"iran":114,"usApproval":134,"links":140,"populations":159},"zolmitriptan",1,{"fa":7,"en":8},"زولمیتریپتان","Zolmitriptan","nervous-system",{"fa":11,"en":12},"تریپتان (آگونیست 5-HT1B\u002F1D)","Triptan (5-HT1B\u002F1D agonist)",[14],{"name":15,"market":16},"Zomig","US",[18,19,7],"zomig","زومیگ",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-2-5","tablet","oral","2.5 mg tablet (functionally scored)",{"amount":27,"unit":28,"perUnit":23,"scored":29},2.5,"mg",true,[16],[32],{"source":33,"section":34},"fda-zolmitriptan","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":41,"refs":42},"tab-5","5 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":40},5,false,[16],[43],{"source":33,"section":34},[45],{"id":46,"disease":47,"label":48,"population":51,"type":55,"unit":28,"dose":56,"refs":57,"limits":60,"notes":64},"acute","migraine-acute",{"fa":49,"en":50},"حمله حاد میگرن بزرگسال — ۱٫۲۵ یا ۲٫۵ mg؛ حداکثر تک‌دوز ۵ mg","Acute migraine, adults — 1.25 or 2.5 mg; max single dose 5 mg",{"minAge":52},{"value":53,"unit":54},18,"year","fixed",{"perDose":27,"perDoseMax":39,"dosesPerDay":5},[58],{"source":33,"section":59},"2.1",{"maxPerDay":61,"refs":62},10,[63],{"source":33,"section":59},[65],{"text":66,"refs":69},{"fa":67,"en":68},"در صورت عدم بهبود یا بازگشت پس از ۲ ساعت تکرار؛ حداکثر ۱۰ mg در ۲۴ ساعت. نارسایی متوسط\u002Fشدید کبد: ۱٫۲۵ mg (شدید حداکثر ۵ mg\u002Fروز). با سایمتیدین حداکثر ۲٫۵ mg تک‌دوز و ۵ mg\u002Fروز.","Repeat after 2 h if not resolved or recurs; max 10 mg in 24 h. Moderate\u002Fsevere hepatic impairment: 1.25 mg (severe max 5 mg\u002Fday). With cimetidine max 2.5 mg single and 5 mg\u002Fday.",[70,71,73],{"source":33,"section":59},{"source":33,"section":72},"2.3",{"source":33,"section":74},"2.4",[76,85],{"id":77,"severity":78,"text":79,"refs":82},"ci","block",{"fa":80,"en":81},"بیماری ایسکمیک کرونر یا وازواسپاسم کرونر (پرینزمتال)؛ WPW یا آریتمی مسیر فرعی؛ سابقه سکته، TIA یا میگرن همی‌پلژیک\u002Fبازیلار؛ بیماری عروق محیطی؛ بیماری ایسکمیک روده؛ فشار خون کنترل‌نشده؛ تریپتان یا ارگوت دیگر ظرف ۲۴ ساعت؛ حساسیت.","Ischaemic coronary disease or coronary vasospasm (Prinzmetal); WPW or accessory-pathway arrhythmias; history of stroke, TIA or hemiplegic\u002Fbasilar migraine; peripheral vascular disease; ischaemic bowel disease; uncontrolled hypertension; another triptan or ergot within 24 h; hypersensitivity.",[83],{"source":33,"section":84},"4",{"id":86,"severity":78,"text":87,"refs":90},"maoi",{"fa":88,"en":89},"مهارکننده MAO-A همزمان یا ظرف ۲ هفته.","MAO-A inhibitor concomitantly or within 2 weeks.",[91],{"source":33,"section":84},[93],{"text":94,"refs":97},{"fa":95,"en":96},"ایسکمی و انفارکتوس قلب؛ آریتمی؛ احساس فشار قفسه سینه، گلو یا فک؛ رویداد عروق مغزی؛ سردرد ناشی از مصرف زیاد دارو؛ سندرم سروتونین؛ افزایش فشار خون.","Myocardial ischaemia and infarction; arrhythmias; chest\u002Fthroat\u002Fjaw tightness; cerebrovascular events; medication-overuse headache; serotonin syndrome; increased blood pressure.",[98],{"source":33,"section":99},"5",[],[],[],{"status":104,"reviewer":105,"date":105},"unverified",null,[107],{"regimen":46,"formulation":22,"input":108,"expect":111},{"ageYears":109,"weightKg":110},35,65,{"perDose":27,"tabletsPerDoseRounded":5,"upperPerDose":39},[113],"N02CC03",{"status":115,"forms":116,"refs":129},"registered",[117,121,125],{"code":118,"en":119,"fa":120},"06840","ZOLMITRIPTAN 2.5MG TAB","قرص زولمیتریپتان ۲٫۵ میلی‌گرم",{"code":122,"en":123,"fa":124},"18158","ZOLMITRIPTAN 5MG  SPRAY NASAL","اسپری بینی زولمیتریپتان ۵ میلی‌گرم",{"code":126,"en":127,"fa":128},"20387","ZOLMITRIPTAN 5MG TAB","قرص زولمیتریپتان ۵ میلی‌گرم",[130],{"source":131,"section":132,"url":133},"darooyab-generic","G-865\u002FZolmitriptan","https:\u002F\u002Fwww.darooyab.ir\u002FG-865\u002FZolmitriptan",{"kind":135,"refs":136,"id":139},"ANDA",[137],{"source":33,"section":138},"SPL approval \u002F marketing category","ANDA201779",[141,144,148,151,154,157],{"kind":142,"url":143,"label":139},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=201779",{"kind":145,"url":146,"label":147},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=e6628b7a-0b63-4e6f-a5e7-2fa195265235","FDA Zolmitriptan",{"kind":149,"url":150,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa601129.html",{"kind":149,"url":152,"label":153},"https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa605046.html","Zolmitriptan Nasal Spray",{"kind":155,"url":156,"label":113},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N02CC03",{"kind":158,"url":133,"label":8},"darooyab",{"pregnancy":160,"lactation":169,"pediatric":177,"geriatric":186},{"level":161,"text":162,"quote":165,"refs":166},"caution",{"fa":163,"en":164},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate data on the developmental risk associated with the use of zolmitriptan in pregnant women.",[167],{"source":33,"section":168},"8.1",{"level":161,"text":170,"quote":173,"refs":174},{"fa":171,"en":172},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of zolmitriptan or its metabolites in human milk, the effects on the breastfed infant, or the effects of zolmitriptan and its metabolites on milk production.",[175],{"source":33,"section":176},"8.2",{"level":178,"text":179,"quote":182,"refs":183},"not-established",{"fa":180,"en":181},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","The safety and effectiveness in pediatric patients have not been established.",[184],{"source":33,"section":185},"8.4",{"level":161,"text":187,"quote":190,"refs":191},{"fa":188,"en":189},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.",[192],{"source":33,"section":193},"8.5",1792191573988]